Navigation Links
DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
Date:3/7/2013

083 represents a 'first in class' small-molecule chemotherapeutic. VAL-083 has been assessed in multiple NCI-sponsored clinical studies in various cancers including lung, brain, cervical, ovarian tumors and leukemia.  Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types.  VAL-083 is approved as a cancer chemotherapeutic in China for the treatment of chronic myelogenous leukemia and lung cancer

Based on published research, the mechanism of action of VAL-083 is understood to be a bi-functional alkylating agent; however, the functional groups associated with alkylating events has been shown to differ from other alkylating agents used in the treatment of GBM.

VAL-083 has previously demonstrated activity in cyclophosphamide, BCNU and phenylanine mustard resistant cell lines and no evidence of cross-resistance has been encountered in published clinical studies.  Based on the presumed alkylating functionality of VAL-083, published literature suggests that DNA repair mechanisms associated with Temodar and nitrosourea resistance, such as 06-methylguanine methyltransferace (MGMT), may not confer resistance to VAL-083. 

VAL-083 readily crosses the blood brain barrier where it maintains a long half-life in comparison to the plasma.  Published preclinical and clinical research demonstrates that VAL-083 is selective for brain tumor tissue.

VAL-083 has been assessed in multiple studies as chemotherapy in the treatment of newly diagnosed and recurrent brain tumors.  In general, tumor regression was achieved following therapy in greater than 40% of patients treated and stabilization was achieved in an additional 20% - 30%.  In published clinical studies, VAL-083 has previously been shown to have a statistically significant impact on median survival in high grade gliomas when combined with radiation vs. radiation alone. 

The mai
'/>"/>

SOURCE DelMar Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
2. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
4. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
5. AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
6. Cadence Pharmaceuticals Reports Fourth Quarter and Full Year 2012 Financial Results
7. Inovio Pharmaceuticals Prices $15.1 Million Offering of Common Stock and Warrants
8. Receptos Determines Novel GPCR Structure, Achieves Key Milestone in Collaboration with Ono Pharmaceuticals
9. AVANIR PHARMACEUTICALS ANNOUNCES RESEARCH COLLABORATION WITH DEPARTMENT OF VETERANS AFFAIRS FOR SCREENING PSEUDOBULBAR AFFECT (PBA) SYMPTOMS IN VETERANS WITH TRAUMATIC BRAIN INJURY
10. Cylene Pharmaceuticals and TetraGene Enter Agreement for Quarfloxin and Anticancer Quadruplex Technologies
11. Isis Pharmaceuticals to Present at the Barclays Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2015)... Va. , Aug. 27, 2015  The ... the Food and Drug Administration,s (FDA,s) draft guidance ... reference products and biosimilars, to bear a nonproprietary ... AMCP has been seeking a decision from the ... 18 diverse health care stakeholders urging the agency ...
(Date:8/27/2015)... Biosimilars are not generics and the ... and Drug Administration (FDA) for recognizing that each ... guidance issued today. The FDA,s draft guidance on ... calling for biological products to bear a nonproprietary ... reflects the agency,s thinking that "there is a ...
(Date:8/27/2015)... INDIANAPOLIS , Aug. 27, 2015  Eli Lilly ... Morgan Stanley Global Healthcare Conference on Thursday, September 17, ... and president of Lilly Oncology and Richard Gaynor ... medical affairs for Lilly Oncology, will participate in a ... A live audio webcast will be available ...
Breaking Medicine Technology:AMCP Is Disappointed in FDA's Draft Guidance and Proposed Rule Calling for Suffix on Nonproprietary Names of Biological Products 2Biologics Prescribers Collaborative (BPC) Statement on FDA Draft Guidance entitled "Nonproprietary Naming of Biological Products" 2Lilly to Participate in Morgan Stanley Global Healthcare Conference 2
... , VIENNA, Va., Jan. 11 CEL-SCI Corporation ... a developer of vaccines and therapeutics for the prevention and ... validation of all critical utilities and manufacturing equipment at its ... represents a very important milestone as it allows CEL-SCI to ...
... SANTA MONICA, Calif., Jan. 11 Derycz Scientific (OTC Bulletin Board: ... the flow of information from content publishers to enterprise customers and ... 2010, on the website of DDN ( Drug Discovery ... Peter Derycz, is titled "Speeding the Path to FDA Approval in ...
Cached Medicine Technology:CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 2CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 3CEL-SCI Completes Validation of Manufacturing Facility Allowing It To Commence Manufacturing of Multikine 4Derycz Scientific Featured In DDN (Drug Discovery News) 2Derycz Scientific Featured In DDN (Drug Discovery News) 3
(Date:8/28/2015)... ... August 28, 2015 , ... Drugs ... Dr. James Strawbridge, gives a new approach on solutions in his new book ... the employer and employees getting together for meaningful group meetings. "This would educate ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Nashville Business Journal recently ... in business. Mr. Troy Mizell, Chairman of the Board at MyGenetx, is ... 2015 Veterans Awards will recognize Nashville military veterans who, through their professional and ...
(Date:8/28/2015)... ... ... Gregory K. Toumayan, D.C., Q.M.E., is now treating patients with back pain and associated ... pain, stiffness, muscle spasms, and numbness. , Dr. Toumayan received his Bachelor of ... earn his title of Doctor of Chiropractic from the Palmer College of Chiropractic and ...
(Date:8/28/2015)... ... ... The Quatela Center for Plastic Surgery is excited to bring patients the ... by the Food and Drug Administration to eliminate submental fat, also known as the ... are among the premier cosmetic surgeons in Rochester to offer this innovative procedure.     , ...
(Date:8/28/2015)... , ... August 28, 2015 , ... Mendon, IL, home ... good music and good people, all for a good cause. In its second year, ... sponsored once more by Best Drug Rehabilitation. The “Mission” of “Music With A Mission” ...
Breaking Medicine News(10 mins):Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 2Health News:Healthpointe Welcomes Dr. Gregory K. Toumayan, Chiropractor, to Colton, Temecula, and Perris 3Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3Health News:Best Drug Rehabilitation Sponsors "Music With A Mission" Concert Featuring Avenue Beat 2
... Feb. 8 (HealthDay News) --The U.S. Food and Drug Administration ... safe during some MRI scans. Pacemakers are medical devices ... beats. Until now, patients with pacemakers who needed an MRI ... used by the MRI could disturb the pacemakers, settings or ...
... , TUESDAY, Feb. 8 (HealthDay News) -- Heavy ... adulthood and is associated with long-term alcohol-related problems, researchers ... reducing drinking among older teens not only prevents immediate ... problems, the study authors pointed out. The researchers ...
... at the University at Buffalo have devised two new ... important molecules from losing their shape and degrading in ... the development of peptide-based drugs against diseases including cancer. ... than existing techniques, one of which employs an expensive ...
... (HealthDay News) -- Babies who are exposed to HIV at ... levels of antibodies to diseases such as whooping cough, tetanus ... samples from 104 HIV-infected and uninfected South African women and ... of the infants at 16 weeks of age. The samples ...
... (HealthDay News) -- Repeat cases of shingles may be more ... long-held belief that people only get shingles once in a ... rash and sometimes severe pain. The condition is caused by ... Center in Rochester, Minn., analyzed the medical records of nearly ...
... Ariz., Feb. 8, 2011 The Muscular Dystrophy Association ... new research to advance understanding of disease processes and ... and other related neuromuscular diseases affecting more than a ... possible by generous public support of the MDA Labor ...
Cached Medicine News:Health News:FDA Approves First Pacemaker Deemed Safe During MRIs 2Health News:New techniques for stapling peptides could spur development of drugs for cancer 2Health News:Mom's HIV May Lower Baby's Immunity to Other Diseases 2Health News:Shingles Returns More Often Than Thought 2Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 2Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 3Health News:MDA awards $13.5 million in grants for research treatments for neuromuscular diseases 4
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: